Monday, 7 April 2014

HP and 3D Printing: The Next Big Thing or Paper Tiger?

If there was a heavyweight contest for what is the hottest IP-hi tech subject, the two most likely leading contenders would certainly be patent trolls/NPEs, in
one corner, and 3D printing, in the other. Without choosing between the two, permit me to focus this time around on 3D printing. I have previously considered, here, whether the current structure of the industry, dominated by 3D Systems here, and Stratasys, here, each of which is seeking to become a large tent, if not a one-stop shop, for 3D printing products (and even the materials required), would be disrupted by the entry of a major hi-tech behemoth, which would seek to leverage its overall hi-tech market position to grab a share, if not more. That would set up a potentially interesting clash of branding approaches: while 3D Systems and Stratasys will each continue to seek to carve out an identity as the 3D printing brand of choice, one or more hi-tech multinationals will attempt to extend their overall goodwill and name in the marketplace to capture at least a part of the 3D printing industry.

A material salvo in this direction was shot in this direction late last month, when HP indicated that it was about to enter the 3D printing market. Despite what appears as a bit of a public relations mis-step (it is reported that HP CEO Meg Whitman first stated that the announcement would come in June, but corrected herself a few days later in a blog post, stating that the announcement would come only by the end of the company’s fiscal year, October 2014, here), the upshot is the same—HP appears to be determined to enter the 3D printing field. Few details have been given about what HP is really up to in the run-up to its October 2014 launch. Morsels of information have focused on the claim that HP has finally solved a number of unspecified technical issues as well as a declaration that the first market of interest will be the enterprise market. Against this, a particularly interesting attempt to explain the what and why of HP’s announcement appeared on 28 March on Forbes.com, “Why is HP Entering the 3D Printing Industry?”, here.

According to the piece, the primary reason why HP is entering the 3D printer market "is because a host of core patents such as apparatus for producing parts by selective sintering have either expired or are expiring within a year.” Followers of the industry are aware of this and there have been various views on whether this portends a patent cliff, at least for the incumbents. From the Forbes.com perspective, the effect of the expiry of this first generation of patents seems to be that HP can cherry-pick the information soon to enter the public domain and to leverage its advantages to better exploit this soon-to-be freely available technology (more on this point again below), without having to commit massive R&D funds in this direction. Whether this is so, or whether the patent landscape will more be incremental than that, remain to be seen. Be that as it may, the Forbes.com article also suggests that, together with the expiry of these so-called core patents, HP has made significant progress in reducing the cost of consumables (it should be remembered that the materials to be used in the 3D manufacturing process, and the “razor-blade” business model that is inherent in the sales of these materials, are too often overlooked though commercially central to the 3D industry). As well, HP is reported to have progress in the quality of the additive “print” output as well reducing the printing time, which makes 3D printing less attractive for more batch-like manufacturing.

The article’s attempt to explain why HP’s announced foray in 3D printing will be good for the entire industry is interesting, if not fully convincing. First, the article argues that the mere fact that a major hi-tech multinational company will soon be entering the market “add[s] some momentum to a fledgling industry that is dominated by smaller players and could help counter criticism that the technology is still too immature for widespread consumer adoption.” This is a version of the well-established business management notion of “complementary assets”, here, whereby it is not usually the technological pioneer that ultimately succeeds commercially, but rather the company with manufacturing, marketing and distribution clout. Of course, given the fact that the first generation of patents is reaching expiry, it is a bit of an analytical stretch to refer to 3D Systems and Stratasys and their ilk as freshly-minted pioneer innovators. In any event, whether the presence of HP will give more “gravitas” to the entire industry remains uncertain.

Secondly, Forbes.com points to HP’s “deep pockets”, which “can easily fund any R&D to improve future processes or ink (plastic filament), which costs anywhere between $25 to $45 for a kilogram depending on the quality and manufacturer.” Here, too, whether the mere fact that HP has deeper pockets than smaller rivals such as 3D Systems and Stratasys has not heretofore enabled HP to take a lead role in the 3D printing industry. It is one thing to have the financial means to fund research, but it is quite the opposite to be certain that such R&D will translate into solid and stable national growth. Thirdly, as mentioned above, HP is placed to exploit its distributional channels and other complementary assets, at least in the enterprise space. Finally, even if materials continue to constitute a lucrative part of the 3D printing field, the ability of HP to migrate from its prominent position in the traditional 2D printing world to the quite different requirement of the 3D printing environment is also still an open question (interestingly, a recent radio interview with a fund manager devoted solely to the 3D printing industry failed to mention the HP announcement at all).

Indeed, an early indication whether the mere announcement that HP will enter the 3D printing area will be good for the entire industry can be measured by the direction of the stock price of both 3D Systems and Stratasys since the initial announcement by HP CEO Meg Whitman on 20 March 20. As can be seen from the attached, here and here, the stock prices for both companies have notably declined at the time of the original HP announcement and have wandered even a bit lower since then. Whether this decline is due to the HP announcement or to other factors remains an open question (indeed, the fund manager interviewed seemed to suggest that analysts have been down on the entire 3D printing industry lately and this has affected share prices). Still, the decline is food for thought. The ability of these companies to continue to dominate the industry in the face of HP’s announced entry will no doubt be the subject of intense continued interest for a long time to come.

Friday, 4 April 2014

Tax relief for British creatives: an improving situation

Here are a couple of notes on UK IP-related tax developments.

Not quite -- but the sentiment is welcomed ...
First, according to the British government, the European Commission has now approved a UK proposal for video games tax relief, this being via a 25% repayable tax credit on qualifying production costs. The draft provisions introducing this relief were published in December 2012, ending up as law with the passage of the Finance Act 2013 (Section 36 and Schedule 17, embedding them in Part 15B of the Corporation Tax Act 2009. The new provisions came into force this Tuesday, 1 April, according to a GOV.UK news item, here.

Secondly, a consultation paper has now been published by Her Majesty's Treasury, which is seeking some feedback regarding the design of a new corporation tax relief for theatre productions (plays, musicals, dance, ballet and opera).The basic idea is that the new relief will work much the same way as existing film tax relief, providing an additional corporation tax deduction for qualifying expenditure  such as script fees, casting and rehearsing costs and a payable tax credit of 25% for qualifying touring productions, and 20% for other qualifying productions. If you want to make any comments, you have until 8 May to do so. Further details are available here.

Monday, 31 March 2014

FAST, PIPCU and the IWL: encouraging, but not enough

"FAST welcomes move to restrict ad revenue for pirate sites: PIPCU establishes advertising take down scheme" is the excited headline of a media release that recently tumbled into this blogger's in-box. The release reads as follows:

The Federation Against Software Theft (FAST) has applauded an initiative launched by the Police Intellectual Property Crime Unit (PIPCU), which hopes to starve pirate websites of advertising revenue, making these outfits unprofitable.

PIPCU is funded by the Department for Business, Innovation and Skills and run by the City of London Police to combat IP crimes. Established in 2013, the unit has been instrumental in orchestrating the take down of numerous illicit sites.

Its latest initiative, the Infringing Website List (IWL), will see it working closely with advertisers and the industry to starve pirate sites of the oxygen that is advertising revenue. The IWL is an online portal providing the digital advertising sector with an up-to-date list of copyright infringing sites, as identified by the creative industries and evidenced and verified by the City of London Police unit, so that advertisers can cease placing adverts on these sites.

An initial pilot saw an encouraging trend, with a 12 per cent reduction from major household brands on the identified illegal sites. The pilot also revealed that 46 per cent of ads served to the sites clicked through to fraudulent scams. ..."
While any approach to online piracy that seeks to reduce the volume of advertising revenue enjoyed by pirates is to be welcomed, this blogger doubts whether this approach will even come close to making the sort of inroads into online piracy that will make the business an unattractive proposition.  He would also like to see more attention focused on the banks and credit card companies which receive the monies paid to pirates by IP-owning advertisers, other pirates and consumers alike.  Perhaps if they were to become jointly liable with their pirate clients for acts of online piracy they might make a better job of the sort of due diligence that is so manifestly inadequate today.  Does anyone know how much profit the world's major banking and financial institutions earn from pirate clients? It would be good to know.

Parties interested in signing up to the IWL can email PIPCUIWL@cityoflondon.police.uk

Friday, 28 March 2014

Looking for a challenge? Here's the Project Hatchling innovation competition

Here's something that might appeal to some of the IP Finance weblog's more technically imaginative and commercially savvy readers -- despite the use of the cliched and now obsolescent electric light bulb in the logo on the right:
Project Hatchling 
A new innovation competition open to all inventors and entrepreneurs who have an idea for a brand new product has been launched.  Coller IP, specialists in helping organisations protect, understand, value and commercialise their intangible assets, is working in conjunction with  D2M Innovation, Brand Refinery, and The Turtle MatCompany to set the ball rolling.  Free to enter, the competition winner will receive the support of the competition partners to develop, protect, market and sell their product.

Project Hatchling is an innovation competition open to all inventors and entrepreneurs over 18 and resident in the UK who think that they might have a good idea for a consumer product that could extend the Turtle Mat product family of home furnishings.

The competition will run over three months, opening for entries in early April and culminating in a ‘Dragon’s Den’ style pitch day where the shortlisted entrants will be invited to tell the panel of judges why they believe their idea is the best to partner with. The successful entrant will gain valuable support, commercialising their idea with exposure of their product through Turtle Mats’ distribution network, which includes several major retailers and the customer base of over 80,000 [this appears to be the prize, though the p-word isn't used on the competition website]. Says Jackie Maguire, CEO, Coller IP:
Project Hatchling is all about giving entrepreneurs and inventors the chance to see their product become a commercial reality.  We are all keen to encourage and stimulate UK entrepreneurship and the winning candidate will receive the support of the professional partners to develop, market and sell their product, including IP advice and a direct consumer channel to bring the product to market.  Our partners have strategic links with major high-street retailers and can provide marketing help to ensure rapid promotion and success for the winning new concept.   
Too often in the product development process, key skills in marketing, manufacturing and idea protection are lacking, significantly affecting the chances of success. It is hoped that collaboration between our team and the competition winner, these risks will be reduced and the chances of success increased.”
Phil Staunton , Managing Director,  D2M Innovation said, 
"We are expecting two types of people to enter.  Firstly, people who have developed and protected concepts that are likely to appeal to Turtle's Mats customer base and would benefit from our support to get their product manufactured and in front of the nation's top retailers. And secondly, innovative thinkers who are inspired to think up new ideas to meet the brief appealing to the specified consumer."
The Terms and Conditions advise entrants to obtain guidance on whether their ideas are patentable before entering the competition. further,
In the event that you win the Competition, you acknowledge that Turtle Mat reserves the right to launch the product within a timeframe as deemed appropriate to them 
You are free to make your submission and do not knowingly infringe the copyright or other intellectual property rights of any third party.
You agree that the Project Hatchling team may contact me for additional information and/or samples/prototypes if applicable, or to discuss ways in which their services may support the development of your product in the future.
In the event that you win the Competition, you acknowledge that Turtle Mat reserves the right to rebrand, change the marketing route, and/or adapt the product to make it more marketable or commercially viable.
In the event that you win the Competition, you acknowledge that Turtle Mat reserves the right to market the product where it deems most appropriate.
Duly noted.  This blog will watch with interest to see what happens, and hopes to find out how the funding of the product launch will be handled.

Tuesday, 25 March 2014

Patent Trolls Coming Soon to the Bio-pharmaceutical Industry--and a Roadmap?

In a recent article titled “Patent Trolling: Why Bio and Pharmaceuticals Are at Risk”, Professor Robin Feldman of University of California, Hastings College of Law, and W. Nicholson Price II, Fellow at Harvard Law School, argue that so-called patent trolling is likely to develop in the bio-pharmaceutical industry.  The authors examine the biotechnology patent portfolios of five major universities and find many patents that could be used against players in the relevant industry.  Monetization anyone?  Notably, the authors state:

In deciding whether to undertake this analysis, we lost sleep over whether the potential for harm outweighed the potential benefit. If reform efforts are not undertaken, our work could do no more than provide a handy road map for those who would follow. However, with scattered anecdotal evidence suggesting that monetization is moving into biopharmaceuticals, life sciences trolling is predictable and in its infancy. If reforms are implemented before the problem proliferates, legislators and regulators could cabin the activity before it becomes deeply entrenched and too much harm occurs.

I think the authors’ concerns are well-founded, but more information is always helpful.  The authors’ also note that “the Association of University Technology Managers recently announced that it was re-examining its policies that had recommended against transferring rights to non-practicing entities.”  Would anyone like to expand on any anecdotal evidence about monetization in the bio-pharmaceutical industry? 

In examining why “trolling” may occur in the bio-pharmaceutical industry, the article also explains:

There is much truth to the conventional wisdom. Biotechnology and pharmaceutical research does involve a greater investment of time, money and expertise. This results in fewer patents, fewer targets, and a longer lead time for problems to emerge. In addition, developments in product type and patent rules affect the opportunities for patent demands. Biotech and pharmaceutical products tend to have fewer components, and patents in the field tend to be less broad than the software and business method patents that proliferate in the technology industry.

However, the conventional wisdom suffers from three weaknesses. First, it ignores the role that regulation plays in making some pharmaceutical patents harder to invent around, thus raising the potential hold-up costs of what patents are available to monetize. Second, it assumes a classical model of patent bargaining, rather than the strategic bargaining and suit filing adopted by modern monetizers. Third, it assumes that monetizers will confine themselves to a relatively narrow set of technological targets; while high-tech may be low-hanging fruit, the proliferation and increasing sophistication of monetizers means that other industries are likely to be targeted in the near future.

The article goes on to discuss the specific patents held by five universities that could be used by “trolls.”  (Oh, my.  Now I am losing sleep over this blog post about the article.)  And, on to reform efforts and data, IP Finance reader Dr. Reuven K. Mouallem from Israel has sent me links to two of his papers on “patent trolls.”  One paper discusses the issue of “patent trolls” from the patent quality perspective and the second paper examines statistics/procedures from the USPTO, JPO and EPO that evidence quality problems.